Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.

Related Articles

Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.

J Glob Antimicrob Resist. 2017 May 08;:

Authors: Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Bassetti M

Abstract
Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor combination antibiotic approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal and urinary tract infections due to Gram-negative bacteria, particularly extended-spectrum β-lactamase-producing Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa strains. Here we report a case of MDR P. aeruginosa skin and soft-tissue infection successfully treated with C/T.

PMID: 28495526 [PubMed - as supplied by publisher]